.
MergerLinks Header Logo

Announced

Bio-Techne to acquire Asuragen for $320m.

Financials

Edit Data
Transaction Value£230m
Consideration TypeContingent Deferred Consideration, Cash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Pending

Domestic

oncology testing

Single Bidder

Private

United States

Majority

Acquisition

Biotechnology

Friendly

Synopsis

Edit

Bio-Techne, a global life sciences company, agreed to acquire Asuragen, a biotechnology company, for $215m in cash plus contingent consideration of up to $105m upon the achievement of certain future milestones. "Bio-Techne's global presence, reputation and relationships within the clinical diagnostic and research communities will enable Asuragen to broaden our reach and accelerate penetration into the high-growth molecular diagnostic markets addressed by our portfolio. I am honored to continue to lead the Asuragen team as a part of Bio-Techne. I would like to thank all of the great people of Asuragen for their committed efforts growing our company to this point and am looking forward to the next stage of growth under the Bio-Techne umbrella," Matt McManus, Asuragen Chief Executive Officer.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US